Breakthrough: Wockhardt's Miqnaf Antibiotic Gets Regulatory Nod

Wockhardt received a favorable recommendation from India's national drug regulator for its antibiotic Miqnaf, aimed at treating community-acquired bacterial pneumonia (CABP). Endorsed by the Subject Expert Committee of CDSCO, this marks a crucial step toward final approval, impacting the global burden of pneumonia.

Wockhardt, a prominent pharmaceutical company, announced on Friday that its innovative antibiotic, Miqnaf, has received a positive nod from the national drug regulator for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

The endorsement comes from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), following a detailed examination of Miqnaf's clinical trial data covering non-clinical, US/EU Phase 1, Global Phase 2, and India Phase 3 studies conducted over 15 years.

The affirmative opinion from the SEC positions Miqnaf for the final approval by DCGI, targeting CABP patients, especially those affected by multi-drug resistant strains, a major global health challenge, with 2.4 million annual deaths due to lower respiratory tract infections.

(With inputs from agencies.)